As you and the Congressman are probably aware, it is
possible for private citizens to send in a saliva
|
sample and obtain a detailed sequencing of their DNA.
Humans and our diseases are very |
complicated: the super-category of 'blood cancers' is
often divided into five categories:
|
/1/
Leukemias /2/ Hodgkin lymphomas /3/ non-Hodgkin
lymphomas /4/ Myelomas |
/5/ Others, such as
myelodysplastic syndromes and myeloproliferative
neoplasms. |
Humans at present are estimated to have about 25,000
genes that code for proteins like insulin |
and hemoglobin, and another
25,000 genes that have other functions. It is common
to encounter |
genes that control other
genes, and there are epigenetic factors like
methylization and histone |
modifications that can also
silence genes. After sampling the world-wide genetics
grapevine it |
would seem reasonable to say:
|
/1/ not all cases of leukemia
have a genetic basis – the percentage of leukemias
that do – even when |
divided by type of leukemia –
is an area of vigorous debate. That means someone
could have a |
condition somewhere on the
wide-ranging leukemia spectrum without any obvious DNA
problems. |
/2/ there are currently over
160 genes associated with various named leukemia
syndromes. The |
number of defined
mutations of those genes is in the thousands - and
growing. For example, the |
CEBPA gene on
chromosome 19 in the q13.11 region is implicated in
several types of acute myeloid |
leukemia: if one has one of
six mutations one group of leukemias results; if one
has any of several |
dozen other mutations one of
a different group of leukemias usually results. Of
course, some |
mutations cause no known
problems. |
/3/ it is also the case that
one can have known genetic effects but not display
symptoms. It is poorly |
understood why some genetic
configurations result in early onset (childhood)
leukemias and other |
genetic configurations result
in late onset (older than age 50) leukemias. |
|
Were someone somewhere on
Planet Earth fearful that they had leukemia a
reasonable strategy |
would be to search for a DNA
sequencing company that has a panel (a list of genes)
for leukemia. |
Then the customer has to hope
that the panel includes all of the 160-odd genes – or
that the panel |
at least has the gene
involved in the customer's condition. Alas, things are
more complicated than |
that: the DNA sequencing
company has to have lists of mutations for each gene
so that the |
company can report back that
the customer's sequence for each of the 50,000 genes
purports to be |
normal or is implicated in
leukemia. The lists of genes and their syndromes as
well as the lists of |
mutations of those genes
change over time so a DNA sequence analysis done in
2019 might have |
different results than one
done months earlier. |
|
For the next
page of the attachment click here |